MARKET

IGMS

IGMS

IGM Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.92
+1.87
+3.17%
After Hours: 60.92 0 0.00% 16:00 10/23 EDT
OPEN
59.16
PREV CLOSE
59.05
HIGH
63.00
LOW
58.53
VOLUME
190.15K
TURNOVER
--
52 WEEK HIGH
89.81
52 WEEK LOW
18.89
MARKET CAP
1.87B
P/E (TTM)
-30.2438
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Investigating IGM Biosciences
The shares of IGM Biosciences are up more than 300% since the company went public early this summer.The stock is recovering from a recent decline and a director used it to purchase shares a month ago.A full investment analysis is presented in the paragraphs below.
Seekingalpha · 10/13 09:49
IGM Biosciences starts early-stage study for IgM antibody in solid cancers and NHL
IGM Biosciences (IGMS) has dosed the first patient in Phase 1 trial evaluating IGM-8444, an IgM antibody targeting the Death Receptor 5 (DR5) protein, in patients with solid cancers and non-Hodgkin’s
Seekingalpha · 09/30 12:21
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkins Lymphoma
GlobeNewswire · 09/30 12:00
Calithera Lung Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Calithera initiates Phase 2 trial for lung cancer treatment.Vertex receives FDA approval for cystic fibrosis treatment.IGM Biosciences makes a deal with AbCellera for antibody discovery.
Seekingalpha · 09/28 17:55
AbCellera and IGM Biosciences collaborates to develop antibodies
AbCellera and IGM Biosciences (IGMS) entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies.AbCellera will generate panels of
Seekingalpha · 09/24 20:59
Insider Weekends: Tamara Gustavson Puts $8 Million Into Public Storage
Insider buying increased significantly last week.Notable Insider Buys: Public Storage, IGM Biosciences, Inc., Cassava Sciences, Inc., Intra-Cellular Therapies, Inc., Nikola Corporation.Notable Insider Sells: Scientific Games Corporation, Guardant Health, Inc., Antero Midstream Corporation, The Boston Beer Company, Inc., Zscaler, Inc.
Seekingalpha · 09/21 11:12
Scientific Games and Cracker Barrel See Activist Action
MacAndrews & Forbes, an investment firm controlled by billionaire Ronald Perelman, slashed its investment in gaming supplier Scientific Games. Biglari Capital reported an 8.7% interest in restaurant chain Cracker Barrel.
Barrons.com · 09/18 22:51
IGM Biosciences +15%, named as possible takeover target
IGM Biosciences ([[IGMS]], +15%) is seeing another sharp gain, leaving technical levels well behind.Piper Sandler listed the company today as a potential oncology takeover target after Gilead Sciences' buyout of Immunomedics.IGMS
Seekingalpha · 09/18 16:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IGMS. Analyze the recent business situations of IGM Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IGMS stock price target is 82.33 with a high estimate of 95.00 and a low estimate of 68.00.
EPS
Institutional Holdings
Institutions: 107
Institutional Holdings: 14.07M
% Owned: 45.90%
Shares Outstanding: 30.66M
TypeInstitutionsShares
Increased
37
1.28M
New
31
323.16K
Decreased
11
893.93K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.72%
Pharmaceuticals & Medical Research
+0.77%
Key Executives
Chairman/Independent Director
Michael Loberg
President/Chief Executive Officer/Director
Fred Schwarzer
Chief Financial Officer
Misbah Tahir
Chief Scientific Officer
Bruce Keyt
Other
Daniel Chen
Independent Director
M. Kathleen Behrens
Independent Director
Julie Hambleton
Independent Director
Michael Lee
Independent Director
Kelvin Neu
Independent Director
William Strohl
Independent Director
Christina Topsoe
Independent Director
Jakob Topsoe
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IGMS
IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of IGM Biosciences Inc stock information, including NASDAQ:IGMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IGMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IGMS stock methods without spending real money on the virtual paper trading platform.